Cargando…
A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge
Crescentic glomerulonephritis, also known as rapidly progressive glomerulonephritis, is a syndrome characterized by progressive and rapid deterioration of renal function over the course of weeks to months. Oliguria, hematuria, azotemia, and hypertension are characteristic features of this condition....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114315/ https://www.ncbi.nlm.nih.gov/pubmed/33966476 http://dx.doi.org/10.1177/23247096211013193 |
_version_ | 1783691035752267776 |
---|---|
author | Bell, Stephen Lattanzio, Natalia Abdelal, Qassem Teklie, Yeshanew Alkayali, Talal Wiese-Rometsch, Wilhelmine Sastry, Ashok |
author_facet | Bell, Stephen Lattanzio, Natalia Abdelal, Qassem Teklie, Yeshanew Alkayali, Talal Wiese-Rometsch, Wilhelmine Sastry, Ashok |
author_sort | Bell, Stephen |
collection | PubMed |
description | Crescentic glomerulonephritis, also known as rapidly progressive glomerulonephritis, is a syndrome characterized by progressive and rapid deterioration of renal function over the course of weeks to months. Oliguria, hematuria, azotemia, and hypertension are characteristic features of this condition. Crescentic glomerulonephritis is further classified according to the staining pattern on immunofluorescence. In rare instances, a mixed pattern of injury is encountered as in the case of double antibody-positive rapidly progressive glomerulonephritis (RPGN). This case illustrates the challenge in treatment of double antibody-positive RPGN in an elderly female with no previous renal disease. The patient was found to be positive for anti-GBM antibody and MPO-ANCA. Treatment was initially targeted against MPO-ANCA as the biopsy was most consistent with this process; however, the patient failed to respond to treatment and was subsequently transitioned to oral cyclophosphamide directed against anti-GBM disease. In cases of doubly antibody-positive RPGN with anti-GBM disease and ANCA-associated vasculitis, initial treatment should focus on inducing remission of anti-GBM disease as double antibody-positive disease often presents with the aggressive morbidity and mortality seen in anti-GBM disease, and the chronic risk of relapse seen in ANCA-mediated vasculitis. |
format | Online Article Text |
id | pubmed-8114315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-81143152021-05-19 A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge Bell, Stephen Lattanzio, Natalia Abdelal, Qassem Teklie, Yeshanew Alkayali, Talal Wiese-Rometsch, Wilhelmine Sastry, Ashok J Investig Med High Impact Case Rep Case Report Crescentic glomerulonephritis, also known as rapidly progressive glomerulonephritis, is a syndrome characterized by progressive and rapid deterioration of renal function over the course of weeks to months. Oliguria, hematuria, azotemia, and hypertension are characteristic features of this condition. Crescentic glomerulonephritis is further classified according to the staining pattern on immunofluorescence. In rare instances, a mixed pattern of injury is encountered as in the case of double antibody-positive rapidly progressive glomerulonephritis (RPGN). This case illustrates the challenge in treatment of double antibody-positive RPGN in an elderly female with no previous renal disease. The patient was found to be positive for anti-GBM antibody and MPO-ANCA. Treatment was initially targeted against MPO-ANCA as the biopsy was most consistent with this process; however, the patient failed to respond to treatment and was subsequently transitioned to oral cyclophosphamide directed against anti-GBM disease. In cases of doubly antibody-positive RPGN with anti-GBM disease and ANCA-associated vasculitis, initial treatment should focus on inducing remission of anti-GBM disease as double antibody-positive disease often presents with the aggressive morbidity and mortality seen in anti-GBM disease, and the chronic risk of relapse seen in ANCA-mediated vasculitis. SAGE Publications 2021-05-08 /pmc/articles/PMC8114315/ /pubmed/33966476 http://dx.doi.org/10.1177/23247096211013193 Text en © 2021 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Bell, Stephen Lattanzio, Natalia Abdelal, Qassem Teklie, Yeshanew Alkayali, Talal Wiese-Rometsch, Wilhelmine Sastry, Ashok A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge |
title | A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge |
title_full | A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge |
title_fullStr | A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge |
title_full_unstemmed | A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge |
title_short | A Rare Case of Double Antibody-Positive Rapidly Progressive Glomerulonephritis: A Therapeutic Challenge |
title_sort | rare case of double antibody-positive rapidly progressive glomerulonephritis: a therapeutic challenge |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114315/ https://www.ncbi.nlm.nih.gov/pubmed/33966476 http://dx.doi.org/10.1177/23247096211013193 |
work_keys_str_mv | AT bellstephen ararecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT lattanzionatalia ararecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT abdelalqassem ararecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT teklieyeshanew ararecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT alkayalitalal ararecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT wieserometschwilhelmine ararecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT sastryashok ararecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT bellstephen rarecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT lattanzionatalia rarecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT abdelalqassem rarecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT teklieyeshanew rarecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT alkayalitalal rarecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT wieserometschwilhelmine rarecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge AT sastryashok rarecaseofdoubleantibodypositiverapidlyprogressiveglomerulonephritisatherapeuticchallenge |